Back to articles
Bhavana as Liquid-Assisted Mechanochemistry: Its Role in Phase Transformation, Particle Engineering and Pharmaceutical Performance
Abstract
Background: Bhavana, the repeated processing of powdered materials with a prescribed liquid, combines mechanical work with exposure to a chemically active medium. Its relationship with liquid-assisted mechanochemistry offers a useful basis for studying Ayurvedic pharmaceutical processing, provided that physical size reduction, compositional enrichment and genuine solid-state transformation are distinguished. Objective: To examine the evidence linking Bhavana with phase transformation, particle engineering and pharmaceutical performance, and to identify the experiments needed to establish these relationships. Approach: A narrative review of classical material, primary studies of Ayurvedic preparations, controlled mechanochemistry experiments and official analytical guidance was undertaken. Findings from defined chemical systems were treated as methodological analogues rather than direct proof of mechanisms in complex formulations. Discussion: Direct studies report changes in particle size, surface characteristics, extractive values and selected biological or dosage-form properties after Bhavana. These findings establish that processing can alter the preparation, but frequently do not isolate the effects of mechanical energy from those of added constituents, soaking or drying. Controlled liquid-assisted grinding studies demonstrate that liquid identity, quantity and activity can influence solid-form selection. Applying this framework to Bhavana requires measurements of the changing liquid content, mechanical input and material composition. Phase claims need complementary structural evidence; particle-size claims require clearly stated measurement methods. Improved dissolution, systemic exposure and clinical benefit represent separate outcomes. Conclusion: Bhavana can be investigated as a heterogeneous family of wet mechanical processes with possible mechanochemical effects. Its pharmaceutical value should be established for each preparation through controlled comparisons, reproducible characterization and relevant performance testing. Current evidence does not support universal claims of nanoparticle formation, improved bioavailability or detoxification
Keywords
Keywords: Bhavana; Ayurveda; liquid-assisted grinding; mechanochemistry; phase transformation; particle engineering; dissolution; pharmaceutical quality.
References
1. Agnivesha. Charaka Samhita. Vimana Sthana, chapter 1, Rasa Vimana, verse 22(2) [Internet]. Charak Samhita Research, Training and Skill Development Centre; [cited 2026 Oct 28]. Available from: https://carakasamhitaonline.com/index.php?title=Rasa_Vimana
2. Shan N, Toda F, Jones W. Mechanochemistry and co-crystal formation: effect of solvent on reaction kinetics. Chem Commun (Camb). 2002;(20):2372–2373. doi:10.1039/B207369M.
3. Trask AV, Motherwell WDS, Jones W. Solvent-drop grinding: green polymorph control of cocrystallisation. Chem Commun (Camb). 2004;(7):890–891. doi:10.1039/B400978A.
4. Mitra S, Prajapati PK, Shukla VJ, Ravishankar B. Impact of Bhavana Samskara on physico-chemical parameters with special reference to Gandhaka Rasayana prepared by different media and methods. Ayu. 2010;31(3):382–386. doi:10.4103/0974-8520.77155.
5. Friščić T, Childs SL, Rizvi SAA, Jones W. The role of solvent in mechanochemical and sonochemical cocrystal formation: a solubility-based approach for predicting cocrystallisation outcome. CrystEngComm. 2009;11(3):418–426. doi:10.1039/B815174A
Theodosiou F, Blundell TJ, Evans JSO, Basford P, Fellah N, Cruz Cabeza AJ. Phase diagrams of pharmaceutical solvates from mechanochemistry. Nat Commun. 2026;17(1):1048. doi:10.1038/s41467-025-67806-1.
7. Jagtap CY, Charde V, Rawat H, Dane G, Mishra AK, Narasimhaji CV, et al. The structural and thermal properties of Badarashma Pishti. J Ayurveda Integr Med. 2024;15(6):100989. doi:10.1016/j.jaim.2024.100989.
8. Hackley VA, Clogston JD. Measuring the size of nanoparticles in aqueous media using batch-mode dynamic light scattering. Gaithersburg (MD): National Institute of Standards and Technology; 2015. NIST Special Publication 1200-6. doi:10.6028/NIST.SP.1200-6.
9. Madappattu K, Rajam R. Preparation and physico-chemical analysis of Agnikumara Rasa (B.R Jwaradhikara) prepared with variation in number of Bhavana (levigation). Int J Ayurveda Pharm Res. 2022;10(7):1–6. doi:10.47070/ijapr.v10i7.2462.
10. Chaudhari KR, Savjani JK, Savjani KT, Shah H. Improved pharmaceutical properties of ritonavir through co-crystallization approach with liquid-assisted grinding method. Drug Dev Ind Pharm. 2021;47(10):1633–1642. doi:10.1080/03639045.2022.2042553.
11. Sharma R, Bolleddu R, Maji JK, Ruknuddin G, Prajapati PK. In-vitro α-amylase, α-glucosidase inhibitory activities and in-vivo anti-hyperglycemic potential of different dosage forms of Guduchi (Tinospora cordifolia [Willd.] Miers) prepared with Ayurvedic Bhavana process. Front Pharmacol. 2021;12:642300. doi:10.3389/fphar.2021.642300.
12. Friščić T, Halasz I, Beldon PJ, Belenguer AM, Adams F, Kimber SAJ, et al. Real-time and in situ monitoring of mechanochemical milling reactions. Nat Chem. 2013;5(1):66–73. doi:10.1038/nchem.1505.
13. Gracin D, Štrukil V, Friščić T, Halasz I, Užarević K. Laboratory real-time and in situ monitoring of mechanochemical milling reactions by Raman spectroscopy. Angew Chem Int Ed Engl. 2014;53(24):6193–6197. doi:10.1002/anie.201402334.
14. US Food and Drug Administration. Q14 analytical procedure development: guidance for industry. Silver Spring (MD): FDA; 2024. Available from: https://www.fda.gov/media/161202/download
15. US Food and Drug Administration. Q2(R2) validation of analytical procedures: guidance for industry. Silver Spring (MD): FDA; 2024. Available from: https://www.fda.gov/media/161201/download
16. US Food and Drug Administration. Q1A(R2) stability testing of new drug substances and products: guidance for industry. Rockville (MD): FDA; 2003. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q1ar2-stability-testing-new-drug-substances-and-products
17. US Food and Drug Administration. Drug products, including biological products, that contain nanomaterials: guidance for industry. Silver Spring (MD): FDA; 2022. Available from: https://www.fda.gov/media/157812/download
